As a result, the combination therapy was associated with the increased infiltration of CD8+ T lymphocytes, CD86+-activated monocytic myeloid-derived suppressor cells, and TAMs, ultimately contributing to a robust anti-tumor immune response [8]. The gene discussed is CD8A; the disease is neoplasm.